Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. - Wikidata - wikimedia - TriplyDB

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

http://www.wikidata.org/entity/Q34663603

about

Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review Lenalidomide for the treatment of B-cell lymphoma.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.The clinical development of obinutuzumab for the treatment of follicular lymphoma.Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?FNC efficiently inhibits mantle cell lymphoma growth.SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience.Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.Bendamustine reactivates latent Epstein-Barr virus.Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Follicular Lymphoma: The Management of Elderly Patient.Current regimens and novel agents for mantle cell lymphoma.Therapeutic approaches in patients with newly diagnosed follicular lymphoma.New therapies in non-Hodgkin lymphoma.A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Bortezomib in the treatment of mantle cell lymphoma.Treatment options for mantle cell lymphoma.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Chimeric antigen receptor T-cell therapies for lymphoma.

P2860

Q26783430-D58D7ED7-07B9-496A-A349-943B457443C0 Q27011795-4177383F-9F3B-48A7-92FE-21A6C34727E7 Q28066710-4ED88B2F-453B-4F72-ACE8-5F42D2ADC9DF Q28072397-8E79DAEB-A0D0-4035-B710-09831C764E2E Q28073262-EBA9EF3B-A1B4-4001-8A48-D0105C27AA42 Q28075606-0CFE358E-4AE0-499C-BCAC-1BA52A68C734 Q28087748-4A17D778-8F45-4A10-A266-2A2D1B03E62E Q30249007-1854A71A-1399-44F3-B1E7-F2B5DC50DF08 Q33424956-663E3F82-7AA4-4CFC-BCBD-666CFE339737 Q33425935-A61F1351-F4EE-4705-A8B2-9F75050E7265 Q33565265-4E53A176-A2DB-48AB-B184-52E8A40E921D Q33574197-91BAC67D-A800-42F2-8C53-4778611BDBCD Q33621041-56BCD804-29C5-4333-B92B-A7FABF722F0D Q33877999-47E93AD2-7280-4087-A97F-6236969DD0BF Q34480345-61FD23A0-571D-4EE2-933B-CE7D0619680B Q35483796-7F567E2D-AC98-48AC-A579-113248B0FBA8 Q35979057-98D42568-CA5F-42D4-81DE-E992375355FE Q36278006-84EB7E3F-1462-40B2-B778-DEE4FF1529D5 Q36305803-F2653D52-4729-48FD-A58F-1D6352FC0FAF Q36319779-540DA4B8-57C6-4E07-9D8A-63BD218D8322 Q36400279-586306D0-D6BA-4645-A7BF-384A6251B580 Q36413919-007A939F-83CE-4226-A521-855FB895791C Q36448074-0D2045AD-D27F-4635-8690-1C3D67F7BE2A Q36456078-BB3D2F64-F4E9-48C0-83B2-EB7EA83836C2 Q36934350-1796DBCD-9F6D-4468-BA2D-6B68C2A39A72 Q37037432-36CD0354-57C2-40A0-90C5-83A9EC0031A7 Q37094781-2954ED19-D519-480C-AD69-5E3C7EB792A1 Q37524930-678D9AC7-B756-45E0-9B3C-D15DD804603C Q37577856-916D9D07-9C43-45F9-8B12-9BC6C7FF08E8 Q38224186-988C8874-8599-42AF-8DFF-6A064F2231C9 Q38267041-C783A2C9-5ECC-4EE5-BEBE-A1ABACCFA862 Q38315779-00CBCC65-EEDC-463B-B9A4-D77BA86F2DFD Q38364912-70060824-D194-4CC4-ABBE-6F12B04B4A8D Q38417140-34610632-18AD-4A7C-BEC8-C3851B11E210 Q38535489-FA12E60E-FCD3-41A3-BC2F-511A0C84D21F Q38548134-89327A59-7AE0-434C-9062-D74F5640C77D Q38582650-91E07E5D-DCD7-48E5-91C5-5859DD86868A Q38584922-D6EB557C-2F23-417E-956D-D853AA2A5FA9 Q38594531-0CCAB7EF-672F-4CBB-9BF8-54A6B581C96E Q38600697-1401CAB6-7F92-4DCB-81F3-3D147C4741EA

P2860

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

http://www.wikidata.org/entity/Q34663603

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@ast

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@en

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@nl

type

label

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@ast

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@en

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@nl

prefLabel

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@ast

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@en

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@nl

P1433

Q34663603-081769A4-2FCA-4616-84B3-094EC7ED05FC

P1476

Q34663603-D22CCDDB-2B66-4083-8503-D6D085E49ADE

P2093

Q34663603-1088994E-47E9-4DED-B067-673DD84E820E

Q34663603-3A1B935E-3637-4CA4-AB03-9D1666F2A77E

Q34663603-3D5361D7-FD9C-4A02-94F4-367EE48D9F76

Q34663603-41885474-F04E-4764-9596-C2783B7A97B1

Q34663603-53DF2899-E439-4A5E-8584-AD9FAC8FC47B

Q34663603-677568DA-4F24-46FE-80FD-971FFE58DE78

Q34663603-7441C925-2EA0-4311-B476-DF0EC78E9441

Q34663603-8C9D6B0A-C089-41C0-900F-4D120A8083C8

Q34663603-91B13EC3-5AF7-497A-A7C5-D0E7750C02C6

Q34663603-BBCE906B-F85C-44D6-B4DB-EFBC94586830

P2860

Q34663603-0FBD8C52-B4A3-40AE-B86D-81B62AF500CE

Q34663603-16A3BFC6-8A9F-4435-8C11-4815C492656E

Q34663603-2359DC5F-E0D8-47F4-881B-2AA8C4FE58A4

Q34663603-63959297-5E87-4696-9AAB-5963C7ED9F3C

Q34663603-7E25F9E8-AAF6-4246-92E1-EE0B2AFFB32C

Q34663603-84DC5B6C-A471-4126-9C77-73A250162233

Q34663603-A8FB3DF3-C363-4ED1-93CA-A5259B5F19FB

Q34663603-C2704166-02E8-468A-92B5-3A9D21A4F16B

Q34663603-CBA2C02B-EFE4-4356-9541-2430CDEC3B11

Q34663603-D3DAD4E5-CAD1-472C-97CA-DCD56041E86C

P304

Q34663603-80C14DA5-8BA1-4136-B1CD-F98BC0ED8021

P31

Q34663603-7A314464-5154-498C-BD84-49AD2CF23EC1

P356

Q34663603-07629BF5-56F8-40A7-98C0-B8A6F050E18B

P407

Q34663603-FB7EC872-70C2-4236-BD15-6A1159C1FC49

P433

Q34663603-FA0ACD16-1744-40E5-B425-B035039D23C7

P478

Q34663603-9B42ADBE-F7D5-4C96-947E-12EC18440C90

P50

Q34663603-188FEF2B-BA45-498B-9834-56247C0C5ED9

P577

Q34663603-D4C296AE-51C3-4421-8A4B-A341BA2AC884

P5875

Q34663603-7E82F2AF-A50A-4B2C-AD1C-AE14C93F4B07

P698

Q34663603-AA13F2E6-0BA4-4A7E-AE37-86C5B942FB65

P932

Q34663603-A870D458-08F6-44BD-ADB1-0EB9C41CE19D

P356

BLOOD-2013-11-531327

P1433

P1476

Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.

@en

P2093

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

David Macdonald

http://www.w3.org/2001/XMLSchema#string

David Simpson

http://www.w3.org/2001/XMLSchema#string

Doreen M Hallman

http://www.w3.org/2001/XMLSchema#string

John M Burke

http://www.w3.org/2001/XMLSchema#string

Kathryn Kolibaba

http://www.w3.org/2001/XMLSchema#string

Ling Chen

http://www.w3.org/2001/XMLSchema#string

Mark Hertzberg

http://www.w3.org/2001/XMLSchema#string

Michael Craig

http://www.w3.org/2001/XMLSchema#string

Mihaela Munteanu

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma

Follicular lymphoma in the United States: first report of the national LymphoCare study.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

Revised response criteria for malignant lymphoma.

P304

2944-2952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-11-531327

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260485954

http://www.w3.org/2001/XMLSchema#string

P698

24591201

http://www.w3.org/2001/XMLSchema#string

P932

4260975

http://www.w3.org/2001/XMLSchema#string